Tagged with IP

Indonesia Endang Hoyaranda, Commissioner and President Director at Prodia Group, elaborates on Prodia’s pioneering spirit when implementing its diversification business strategy and explains how the company has successfully completed its IPO process on the Indonesian stock exchange (IDX). Prodia recently completed its IPO in the Indonesian stock market (IDX) issuing 25…

Taiwan Eugene Huang, chairman, and Hua-Lin Wu, consultant of Blue Blood Biotech Corp., provide insightful information on BB-101, a protein proven to be efficient for wound healing, while sharing their vision for the future growth of the company through partnerships with big pharmaceutical companies. Could you introduce yourself to our executive…

Mexico An ambassador for Philips’ global vision of spearheading innovation, business leader of Philips Personal Health Mexico, Eduardo Gutierrez, shares his insights on the key growth drivers in the segment, digitalization, connectivity, and his personal motivations in the role. To begin, can you introduce the main facets of your role at…

Taiwan Philips Healthcare Taiwan general manager, Jan Poon, talks about the innovative approach that Philips aims to implement in the local market; spanning from establishing a digital platform to working with government when ensuring the sustainability of Taiwan’s healthcare system. You have recently become GM for Philips Taiwan. What have been…

Taiwan Ming-Kuei Jang, founder and CEO of Aprinoia, a very promising Taiwan-based company focused on the development of groundbreaking imaging tracers and therapeutics targeting tau-related neurodegenerative diseases, provides insights into the company’s rapid development over the past two years, its R&D strategy, and its eagerness to partner with both academia and…

Taiwan Jacob Lee, co-founder and CEO of DTCO, a Taiwan-based company focused on industrial blockchain services, documents the disruptive impact that the development of the blockchain technology in the healthcare and life sciences sectors could entail for both patients and healthcare providers. He also provides insights into the in-house development of…

Japan Eric Delarge, general manager and representative director of Servier Japan, recently became the first member of the international pharma industry to join bioIPSeeds, an innovative tool aiming to foster early stage collaboration between academia and the global industry, which also stands as the first application of the blockchain technology in…

Taiwan Carol Cheng, COO of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), the association gathering 28 Taiwan-based, R&D-driven biopharmaceutical companies, highlights the association’s eye-catching initiative to boost international collaboration between academia and the global industry, thanks to the recent set up of the BioIPSeeds® platform, which proudly stands as the first…

Taiwan Ben Chien, Chairman, President and CEO, of Foresee Pharmaceuticals, one of Taiwan’s most vibrant success stories, discusses how Foresee has achieved successful phase III results for its prostate cancer treatment, FP-001, IPOed and entered into a partnership agreement with Ferring in the last year alone. In addition, he discloses how…

Taiwan Wu Tsung-Tsong, Minister Without Portfolio of the Republic of China (Taiwan) supervises and coordinates Taiwan’s Biomedical Industry Innovation Program. In this exclusive interview, he documents his main priorities and the government’s unrivalled commitment to further enhancing the attractiveness of Taiwan’s biotech ecosystem and bolstering a win-win relationship between Taiwan, the…

Greece In the price versus value discussion brought on by Greece’s economic crisis, Philips’ message is clear: they offer novel solutions that can do more for less and place the patients at the center. Philips Hellas’ Managing Director, Panagiotis Mparas, speaks about the company’s healthcare footprint in Greece; reconciling the corporate…

Switzerland Susanne Hoeppner, GM of Astellas Switzerland and board member of vips, discusses her key priorities, the culture of Swiss pharma, and the industry-wide push for faster approval times. Ms. Hoeppner, in addition to your role as general manager of Astellas, we understand you also have leadership role within the industry…